No Detail Found!

Rosuvastatin Restrains the Headway of Experimentally Induced Liver Fibrosis: Involvement of NF-κB and Nrf2/HO-1 Signaling Pathway

Author(s)
Khaled Ghaith Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University,,Egypt
Mostafa Abbas Shalaby Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University,,Egypt
A Ramadan Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University,,Egypt
Sahar S. Abd El-Rahman Department of Pathology, Faculty of Veterinary Medicine, Cairo University,,Egypt
Hany M. Fayed Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre,Giza,Egypt
Abstract
The serious health issue of liver fibrosis causes significant morbidity and mortality. Hepatic fibrosis does not currently have a conventional treatment due to its complicated pathophysiology. Statins are well-known by their Pleiotropic effects such as anti-inflammatory, antiapoptotic and antifibrotic actions. This investigation aimed to mark whether rosuvastatin could prevent the rat liver fibrosis caused by thioacetamide (TAA). Following two weeks of TAA injection, ROS (5 and 10mg/kg, daily) was given orally concurrently for further four weeks. ROS markedly decreased the upsurge in serum aminotransferase activities (AST and ALT) and restored albumin level. The increased hepatic glutathione (GSH) content and super oxide dismutase (SOD) activity, along with the declined malondialdehyde (MDA) level, showed ROS antioxidant capabilities. Further, heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) were both upregulated by ROS treatment while decreased the levels of nuclear factor-?B (NF-?B), p-NF-?B, tumor necrosis factor-a (TNF-a) and Interleukin 6 (IL-6). Additionally, ROS upregulated considerably the gene expression of Nrf2 and downregulated PI3K gene expression. Moreover, expression of alpha smooth muscle actin (a-SMA) was reduced while Nrf2 protein expression was elevated by ROS. Thus, it can be concluded that rosuvastatin could protect liver tissue against progression of TAA-induced fibrosis. This can be at least partially due to its antioxidant and anti-inflammatory effects via activation of Nrf2/HO-1 pathway and downregulation of NF-kB.
Publication Details
Page(s) 366-374
Published Journal: International Journal of Veterinary Science, Volume: 12, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Liver fibrosis, Rosuvastatin, thioacetamide, Nrf2, HO-1
0

Citations

0

Downloads

43

Views